As of close of business last night, AMGEN Inc.’s stock clocked out at $274.42, down -0.65% from its previous closing price of $276.21. On the day, 1668742 shares were traded.
Ratios:
To gain a deeper understanding of AMGN’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 13.44 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 19.98. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.65. In the meantime, Its Debt-to-Equity ratio is 10.50 whereas as Long-Term Debt/Eq ratio is at 10.25.
On February 07, 2024, Leerink Partners Downgraded its rating to Market Perform which previously was Outperform and also lowered its target price recommendation from $324 to $318.
Daiwa Securities Upgraded its Neutral to Buy on December 21, 2023, whereas the target price for the stock was revised from $264 to $320.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 04 ’23 when Grygiel Nancy A. sold 2,096 shares for $273.03 per share. The transaction valued at 572,276 led to the insider holds 10,874 shares of the business.
Graham Jonathan P sold 10,000 shares of AMGN for $2,728,136 on Nov 08 ’23. The EVP, Gen. Counsel & Secy. now owns 28,078 shares after completing the transaction at $272.81 per share. On Sep 19 ’23, another insider, AMGEN INC, who serves as the 10% Owner of the company, bought 1,764,705 shares for $17.00 each. As a result, the insider paid 29,999,985 and bolstered with 35,368,653 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AMGN now has a Market Capitalization of 148.02B and an Enterprise Value of 201.68B. As of this moment, AMGEN’s Price-to-Earnings (P/E) ratio for their current fiscal year is 21.98, and their Forward P/E ratio for the next fiscal year is 13.03. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.25 while its Price-to-Book (P/B) ratio in mrq is 23.58. Its current Enterprise Value per Revenue stands at 7.15 whereas that against EBITDA is 13.63.
Stock Price History:
Over the past 52 weeks, AMGN has reached a high of $329.72, while it has fallen to a 52-week low of $211.71. The 50-Day Moving Average of the stock is 287.38, while the 200-Day Moving Average is calculated to be 271.03.
Shares Statistics:
It appears that AMGN traded 3.00M shares on average per day over the past three months and 2.34M shares per day over the past ten days. A total of 535.40M shares are outstanding, with a floating share count of 534.62M. Insiders hold about 0.24% of the company’s shares, while institutions hold 78.86% stake in the company. Shares short for AMGN as of Mar 15, 2024 were 11.11M with a Short Ratio of 3.70, compared to 11.09M on Feb 15, 2024. Therefore, it implies a Short% of Shares Outstanding of 2.07% and a Short% of Float of 2.08%.
Dividends & Splits
With its trailing 12-month dividend rate of 8.52, AMGN has a forward annual dividend rate of 8.64. Against a Trailing Annual Dividend Yield of 3.08%, it implies a Forward Annual Dividend Yield of 3.26%. The stock’s 5-year Average Dividend Yield is 2.97. The current Payout Ratio is 68.24% for AMGN, which recently paid a dividend on Jun 07, 2024 with an ex-dividend date of May 16, 2024. Stock splits for the company last occurred on Nov 22, 1999 when the company split stock in a 2:1 ratio.
Earnings Estimates
As of right now, 18 analysts gave their recommendation on the stock of the company. On average, analysts expect EPS of $3.97 for the current quarter, with a high estimate of $5.16 and a low estimate of $3.63, while EPS last year was $3.98. The consensus estimate for the next quarter is $4.98, with high estimates of $5.62 and low estimates of $4.64.
Analysts are recommending an EPS of between $20.47 and $19.01 for the fiscal current year, implying an average EPS of $19.57. EPS for the following year is $21.16, with 26 analysts recommending between $22.95 and $18.63.
Revenue Estimates
In the current quarter, 16 analysts expect revenue to total $7.54B. It ranges from a high estimate of $8.19B to a low estimate of $7.36B. As of the current estimate, AMGEN Inc.’s year-ago sales were $6.11B, an estimated increase of 23.50% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $8.33B, an increase of 19.20% less than the figure of $23.50% in the same quarter last year. There is a high estimate of $8.66B for the next quarter, whereas the lowest estimate is $8.11B.
A total of 28 analysts have provided revenue estimates for AMGN’s current fiscal year. The highest revenue estimate was $33.77B, while the lowest revenue estimate was $32.46B, resulting in an average revenue estimate of $33.03B. In the same quarter a year ago, actual revenue was $28.19B, up 17.20% from the average estimate. Based on 27 analysts’ estimates, the company’s revenue will be $34.16B in the next fiscal year. The high estimate is $37.71B and the low estimate is $32.63B. The average revenue growth estimate for next year is up 3.40% from the average revenue estimate for this year.
